&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-06-01, 13:00

Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Edith Snider

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-04-13, 19:00

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Micheal Moe

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-25, 23:15

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.
Tamika Gonzalez

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-11, 22:10

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-01-06, 16:00

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-11, 10:05

Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
Kristi Tafoya

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-01-24, 00:40

Workplace Options Unveils Comprehensive & Compassionate Return-to-Work Program for Cancer Survivors

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-01-07, 20:00

Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Bud Eliott

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Monique Kunkel

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Melvina Mahler

Notified -

Popular Posts